About the Company
Spotlight Innovation Inc. identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources.
We provide value-added capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance.
Goals, Objectives and Strategy
- Acquire intellectual property (IP) rights to innovative and proprietary medical technologies
- Target rare, neglected and emerging diseases with clear unmet medical needs
- Provide value-added development capability and funding to fulfill requirements for filing Investigational New Drug (IND) applications
- Commercialize technologies via:
- Strategic alliance
- Generate near-term revenue to support long-term product development programs
Spotlight Innovation Forms Corporate Partnership with University of Iowa Athletics to Promote New Chronic Pain Relief Product “Venodol”
URBANDALE, IA–(Marketwired – Sep 27, 2017) – Spotlight Innovation Inc. ( OTCQB : STLT ) today announced that it has formed a corporate partnership with University of Iowa Athletics that will provide ongoing radio and digital media visibility for the Venodol brand and for Venodol...
Spotlight Innovation Enters into Sponsored Research Agreement with Indiana University to Develop New Therapies for Spinal Muscular Atrophy
URBANDALE, Iowa, Aug. 16, 2017 /PRNewswire/ — Spotlight Innovation Inc. (STLT) today announced that the Company has entered into a Sponsored Research Agreement with Indiana University to support research directed by Elliot Androphy, M.D., aimed at developing safe and effective drugs to treat patients with spinal...
Venodol™ is a Non-opioid, Non-addictive Over-the-Counter Alternative to Opioid and Steroidal Analgesics URBANDALE, Iowa, Aug. 7, 2017 /PRNewswire/ — Spotlight Innovation Inc. (STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that its subsidiary Caretta Therapeutics’ new over-the-counter chronic pain...
TransMedia Group to Provide Public Relations Support for Venodol, a New Over-the-counter, Non-addictive Analgesic for the Treatment of Chronic Pain URBANDALE, Iowa, July 11, 2017 /PRNewswire/ — Spotlight Innovation Inc. (STLT) today announced that its subsidiary Caretta Therapeutics, LLC, has...